RecruitingPhase 2NCT05565495

The Effects of ECMO on the Pharmacokinetics of Hydromorphone

Sponsor

Xiaobo Yang, MD

Enrollment

26 participants

Start Date

Jan 1, 2022

Study Type

INTERVENTIONAL

Conditions

Extracorporeal Membrane Oxygenation

Summary

The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

Between the ages of 18 and 80;
Using hydromorphone for pain relief;
Using ECMO for more than 96h

Exclusion Criteria6

Allergic to hydromorphone;
Use of CRRT during ECMO;
Liver function Child-Pugh B, C grade;
Pregnancy;
Intestinal obstruction;
Refused to sign the informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHydromorphone

Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.